AB056. SOH21AS189. The CTS5 score as a predictor of late distant recurrence: a systematic review and meta-analysis

Background: The Clinical Treatment Score post-5 years (CTS5) integrates four clinicopathologic variables to estimate the residual disease recurrence risk in estrogen receptor-positive (ER+) breast cancer patients who have been treated with 5 years of adjuvant endocrine therapy (AET) and have remained distant recurrence free at 5 years post-diagnosis. This study aimed to determine the accuracy of the CTS5 in predicting actual distant recurrence rates.